Regeneron
Trade Regeneron 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About REGN
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara.
REGN Key Statistics
Stock Snapshot
With a market cap of 75.82B, Regeneron(REGN) trades at $723.22. The stock has a price-to-earnings ratio of 17.11 and currently yields dividends of 51.0%.
As of 2026-05-06, Regeneron(REGN) stock has fluctuated between $700.00 and $724.90. The current price stands at $723.22, placing the stock +3.3% above today's low and -0.2% off the high.
Regeneron(REGN) shares are trading with a volume of 295.76K, against a daily average of 867.06K.
In the last year, Regeneron(REGN) shares hit a 52-week high of $821.11 and a 52-week low of $476.49.
In the last year, Regeneron(REGN) shares hit a 52-week high of $821.11 and a 52-week low of $476.49.
REGN News
In late April 2026, Regeneron Pharmaceuticals reported first-quarter 2026 revenue of US$3,605.4 million and net income of US$727.2 million, affirmed a quarterly...
In a report released yesterday, Salveen Richter from Goldman Sachs maintained a Buy rating on Regeneron, with a price target of $968.00. Unlock hedge fund-leve...
Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) presented results from the REMODEL Phase 4 trial demonstrating that Dupixent showed significant and clinically...
Analyst ratings
77%
of 31 ratingsMore REGN News
Key Points Its stock is down more than 11% this year, but there's reason for optimism. The biotech reported a 19% rise in revenue in the first quarter, year o...
Advertisement What recent performance signals about Regeneron Pharmaceuticals (REGN) With no single headline event driving Regeneron Pharmaceuticals (REGN) to...
In a report released on April 29, Salveen Richter from Goldman Sachs assigned a Buy rating on Regeneron, with a price target of $968.00. Unlock hedge fund-leve...
BMO Capital analyst Evan Seigerman maintained a Buy rating on Regeneron yesterday and set a price target of $900.00. Unlock hedge fund-level data and powerful...
Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) on Wednesday reported first-quarter adjusted earnings of $9.47 per share, up 15% year-over-year, beating the consen...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.